

**LOTTE HOLDINGS, Healthcare and Biopharmaceutical Corporate Venture
Capital Announces Investment in Physiologas Technologies**

LOTTE HOLDINGS CO., LTD. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE HOLDINGS”) announces an investment in Physiologas Technologies (Japan; hereinafter “Physiologas”), a pioneering Japanese medical device company developing next-generation hemodialysis system aimed at transforming chronic kidney disease care.



(※The photo is for reference only)

Founded in 2020, Physiologas is a preclinical stage medical device company that is developing a compact, easy-to-use, at-home hemodialysis device equipped with proprietary dual adsorption filters, in-line ion monitoring, and remote physician monitoring capabilities. With its innovative approach to dialysate regeneration and toxin removal, Physiologas eliminates the need for conventional water infrastructure, making dialysis more accessible and flexible for patients that seek solutions to current chronic kidney disease treatments.

The investment from LOTTE HOLDINGS Healthcare and Biopharmaceutical CVC marks its first investment in the medical device sector, underscoring its commitment to expanding into high-impact healthcare technologies, as well as biopharmaceuticals. This investment round, led by LOTTE HOLDINGS, will support Physiologas in finalizing its prototype, conducting preclinical testing, and preparing for regulatory consultations

with PMDA and FDA. The company aims for device approval in Japan by 2029, with subsequent launches planned globally.

The investment in Physiologas is aligned with LOTTE HOLDINGS' enduring commitment to advancing healthcare innovation and addressing global health challenges. Chronic kidney disease (CKD), which affects over 800 million people worldwide, remains one of the leading causes of mortality – particularly among patients without access to dialysis or transplantation. By supporting Physiologas, LOTTE HOLDINGS aims to democratize CKD treatment and make a meaningful social impact through the development of accessible, next-generation hemodialysis solutions, while enhancing its healthcare portfolio with medical device innovations.

“We believe Physiologas Technologies has the potential to revolutionize conventional hemodialysis with its simple yet truly innovative technology, providing global solutions and improving the quality of life for CKD patients worldwide”, said Managing Partner Dr. Joon Paek from LOTTE HOLDINGS CVC.

About LOTTE HOLDINGS CO., LTD. (<https://lotte-hd.com/>)

Company Name	LOTTE HOLDINGS CO., LTD.
Headquarters	3-20-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Representative Director	Genichi Tamatsuka
Website	https://lotte-hd.com/
CVC Website	https://lotte-hd.com/en/business/lifescience/bio-cvc/

Starting with its core confectionery and ice cream businesses, LOTTE HOLDINGS has expanded into a wide range of business fields, including professional baseball team management, real estate, finance, corporate venture capital, hotels, and healthcare. Looking ahead, LOTTE HOLDINGS aims to drive further innovation in its core food business while pursuing new growth opportunities by leveraging business synergies between Japan and South Korea.

The LOTTE Group began its operations in 1948 with the manufacturing and selling of chewing gum in Tokyo, Japan. Today, with headquarters in both Japan and South Korea, the LOTTE Group operates across more than 30 countries and regions worldwide, spanning businesses including food, retail, finance, biopharmaceuticals, healthcare, data centers, hotels and resorts, entertainment, and construction. Guided by its vision as a "Lifetime Value Creator," the LOTTE Group is committed to delivering sustainable value throughout every moment of people's lives.

About Physiologas Technologies

Founded in 2020 and headquartered in Japan, Physiologas Technologies is a preclinical-stage medical device company developing advanced hemodialysis systems for in-center, mobile, and home hemodialysis. Its proprietary technology features dual adsorption filters, in-line ion monitoring, and remote physician monitoring, enabling safer, more efficient, and more accessible dialysis treatment. By eliminating the need for conventional water infrastructure and offering compact, flexible solutions, Physiologas aims to transform chronic kidney disease care and improve the quality of life for patients worldwide.

For more information, please visit <https://physiologas.co.jp/en-index.html>.